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Abstract
Previous work has demonstrated that the function of
extrahepatic cytochrome P450 CYP1A1 is dependent on
the availability of heme. CYP1A1 is involved in the acti-
vation of polyaromatic hydrocarbons. In the present
study we used a transgenic mouse model with chronic
impairment of heme synthesis – female porphobilinogen
deaminase-deficient (PBGD-/-) mice – to investigate the
effects of limited heme in untreated and b-naphthofla-
vone (b-NF)-treated animals on the function of CYP1A1
in brain. The heme content of PBGD-/- mice was dimin-
ished in the liver and brain compared to wild types. In
the liver, partial heme deficiency led to less potent induc-
tion of CYP1A1 mRNA after b-NF treatment. In the brain,
CYP1A1 protein was detected not only at the endoplas-
mic reticulum (ER), but also in the cytosol of PBGD-/-
mice. Furthermore, 7-deethylation of ethoxyresorufin, an
indicator of CYP1A1 metabolic activity, could be restored
by heme in cytosol of PBGD-/- mouse brain. Independent
of the genotype, we found only one cyp1a1 gene prod-
uct, indicating that the cytosolic appearance of CYP1A1
most likely did not originate from mutant alleles. We con-
clude that heme deficiency in the brain leads to incom-
plete heme saturation of CYP1A1, which causes its
improper incorporation into the ER membrane and per-
sistence in the cytosol. It is suggested that diseases
caused by relative heme deficiency, such as hepatic por-
phyrias, may lead to impaired hemoprotein function in
brain.
Keywords: apoprotein; cytochrome P450; membrane
insertion; porphyria; transgenic mouse.
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Introduction
Heme is one of the body’s pivotal molecules. It fulfils a
vital role in cellular oxygen sensing and utilization in all
living organisms from bacteria to humans (Padmanaban
et al., 1989). Heme is the prosthetic group in numerous
hemoproteins, including P450 cytochromes (CYPs) (Ran-
garajan and Padmanaban, 1989; Zhang et al., 1998;
Abraham et al., 2000). CYPs play an important role in the
oxidative metabolism of numerous endogenous and for-
eign compounds (Nelson, 2004). CYPs are active in drug
metabolism and clearance, in cholesterol homeostasis,
and in steroid hormone regulation, not only in the liver,
but also in the brain (Thuerl et al., 1997; Meyer et al.,
2001a,b; Ourlin et al., 2002; Handschin and Meyer, 2003).
CYPs perform their manifold functions as functional holo-
enzymes saturated with heme (Correia and Meyer, 1975;
Jover et al., 1996). Thus, the regulation of heme availa-
bility is of major importance for CYP function. Cellular
levels of heme are regulated by its rate of synthesis and
degradation by the key enzymes d-aminolevulinate syn-
thase 1 (ALAS-1) and the heme oxygenase (HO) system
(Jover et al., 1996; Maines, 2000). However, regulation of
heme availability for CYPs is tissue-dependent. Previous
studies in vitro and in mice, both with pharmacologically
induced acute heme deficiency, have revealed differen-
ces in heme saturation of CYPs and pointed to a role of
heme in the incorporation of apocytochromes into the
endoplasmic reticulum (ER) membrane (Meyer et al.,
2002). A regulatory heme pool tightly regulates heme
synthesis in the liver, but apparently less so in extrahe-
patic tissue (Bissell and Hammaker, 1976b; Giger and
Meyer, 1983).
Porphyrias are inherited or acquired disorders that are
attributable to partial defects in the enzymes of heme
synthesis (porphyrin metabolism), usually in association
with endogenous or exogenous stressors (Daniell et al.,
1997). In certain so-called hepatic porphyrias, patients
have neuropsychiatric symptoms, including autonomic
neuropathy with abdominal pain, vomiting, and hyperten-
sion, and central neuropathies, including motor weak-
ness, paralysis and mental symptoms (Sassa, 2002).
These symptoms may possibly originate from impaired
heme protein function in the brain. Candidate hemopro-
teins in the brain are the nitric oxide synthase, guanylate
cyclase system, tryptophan dioxygenase, mitochondrial
cytochromes, and several isoforms of the CYP superfam-
ily (Jover et al., 2000).
In the present study, we investigated if expression and
function of CYP1A1 is affected in vivo by chronic heme
deficiency in the brain. CYP1A1 is involved in the meta-
bolic activation of polyaromatic hydrocarbons (Hankin-
son et al., 1991). We used a female transgenic mouse
model mimicking one form of hepatic porphyria, acute
intermittent porphyria (AIP). These mice carry a targeted
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Table 1 Heme content of mouse liver and brain after treatment with b-naphthoflavone.
Tissue Genotype Treatment Heme content
Specific Enhancement vs. Genotype influence p
(pmol/mg protein) controls (%) vs. b-NF-WT (%)
Liver WT None 28.85"1.34 –
WT b-NF 70.00"4.87 242.6 – F0.001
PBGD-/- b-NF 59.17"2.55 205.1 -15.5 F0.05
Brain WT None 13.84"0.38 –
WT b-NF 15.96"0.52 15.3 – F0.005
PBGD-/- b-NF 13.66"0.48 -1.3 -14.4 F0.005
WT, wild type. Specific values represent pooled organs from two mice (mean"SEM; ns3). Treatment with b-NF was
performed as described in the materials and methods section.
disruption of porphobilinogen deaminase (PBGD), the
third enzyme of the heme pathway (Lindberg et al., 1996,
1999). PBGD-/- mice have a defined chronic disturbance
of heme biosynthesis, which can be challenged by CYP-
inducing factors. Therefore, we treated the mice with
b-naphthoflavone (b-NF), an inducer of CYP1A1. Here
we demonstrate that gene expression, heme saturation,
and enzyme activity of CYP1A1 are impaired in PBGD-/-
mice after treatment with b-NF. Our results indicate that
diseases causing heme deficiency, such as AIP, could
lead to impaired hemoprotein function in brain.
Results
Measurement of heme content
Initial experiments were designed to determine whether
heme content in the liver and brain of mice is increased
by b-NF-treatment and affected by the PBGD-/- geno-
type. In wild-type mice, b-NF treatment increased heme
content in both liver and brain, with much stronger
enhancement in liver than in brain (Table 1). In PBGD-/-
mice, the b-NF-dependent enhancement of heme con-
tent was lower in liver and brain compared to wild-type
data (Table 1). It is noteworthy that the heme content in
brains of b-NF-treated PBGD-/- mice was similar to that
found in untreated wild-type mice (Table 1).
Regulation of cyp1a1 mRNA expression in liver
In a subsequent experiment, we analyzed if the signi-
ficant reduction in heme content of b-NF-treated
PBGD-/- mice compared to b-NF-treated wild-types
corresponds to diminished cyp1a1 gene transcription.
Therefore, the expression of mRNA in liver of untreated
wild-types, b-NF-treated wild-types and b-NF-treated
PBGD-/- animals was investigated by Northern blot (Fig-
ure 1). As expected, b-NF treatment led to a significant
increase in cyp1a1 mRNA transcription in both geno-
types (pF0.005). Nevertheless, expression of cyp1a1
mRNA originating from b-NF-treated heme-deficient
PBGD-/- mice was clearly lower compared to b-NF-treat-
ed wild-type mice (Figure 1, lanes 1 and 2), indicating a
negative effect of PBGD deletion and reduced heme
availability for cyp1a1 gene transcription (pF0.05). No
mRNA was detectable in untreated liver (Figure 1, lane
3). This finding is due to the fact that gene transcription
of cyp1a1 is usually very low in untreated animals (Gon-
zalez, 1990). GAPDH control data showed no difference
(Figure 1).
Expression of CYP1A1 protein in cellular
subfractions of liver and brain
We next investigated by immunoblot how b-NF treatment
and heme deficiency affect expression and subcellular
localization of CYP1A1 protein in liver and brain (Figure
2). In the liver, the genotype-dependent inducibility of
CYP1A1 protein was in accordance with our findings
investigating mRNA expression (see Figure 1). b-NF
treatment led to the expected induction of CYP1A1 in
both wild-types and PBGD-/- mice (pF0.001), but with
less potency in subfractions of PBGD-/- mice, for which
a lower CYP1A1 protein signal was observed compared
to wild-type mice (Figure 2A) (pF0.05). CYP1A1 was
located almost exclusively in microsomes, independent
of treatment and genotype.
In brain, we observed a striking difference in CYP1A1
expression between b-NF-treated wild-types and
PBGD-/- mice (Figure 2B). b-NF treatment led to a 1.4-
fold increase in CYP1A1 in microsomes of wild-types
compared to PBGD-/- mice (pF0.001). In addition, cyto-
solic CYP1A1 was detected, which was two-fold higher
in the PBDG-/- mice compared to the wild-type animals
(pF0.05). In untreated mice, CYP1A1 was not detectable
in the brain (Figure 2B).
Ethoxyresorufin-O-deethylase (EROD) activity of
CYP1A1 in mouse brain is dependent on genotype
and b-NF induction
The investigation of CYP1A-specific EROD activity in
brain subfractions matched our findings from immuno-
blotting experiments. In untreated mice, no or only neg-
ligible EROD activity could be found in any subfraction,
whereas treatment of the mice with b-NF led to remark-
able increase in EROD activity in all subfractions tested
(Figure 3). EROD activity was found predominantly in the
microsomes, with no significant differences between
wild-types and PBGD-/- mice (Figure 3A). The EROD
activity detectable in the cytosol revealed clear depend-
ence on genotype after treatment of mice with b-NF.
Cytosolic EROD activity of PBGD-/- mice appeared to be
two-fold higher than in wild-types, which reflects a
remarkable fraction of non-membrane bound CYP1A1 in
the brain (Figure 3A) (pF0.005). This genotype-depend-
ent difference in cytosolic EROD activity remained,
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Figure 1 Expression of cyp1a1 mRNA in liver from wild type
and PBGD-/- mice (Northern blot analysis).
(1) b-NF-induced wild types; (2) b-NF-induced PBGD-/- mice;
and (3) untreated wild types, with 5 mg of total RNA loaded on
each lane. In the case of cyp1a1 mRNA, a 294-bp probe located
on exon 7 was used for hybridization (see materials and meth-
ods). GAPDH was used as a reference. Statistical significance
is demonstrated by asterisks (**pF0.005; *pF0.05).
although less striking, after the addition of 8 mM hematin
(Figure 3B). Addition of hematin is reported to saturate
and reconstitute the CYP apoprotein fraction (Omiecinski
et al., 1980). We observed a three-fold enhancement of
EROD activity in cytosol in PBGD-/- mice, and five-fold
enhancement in wild-types, after the addition of hematin
(Figure 3B). In microsomes, however, hematin caused a
reduction in EROD activity (pF0.05).
Gene products of cyp1a1
To examine if cytosolic CYP1A1 originates from an allelic
or splice variant of cyp1a1 leading to either cytosolic or
microsomal protein, we generated a gene-specific probe
designed to recognize sequences of exon 7. This probe
should allow the detection of CYP1A1 gene products
with differences in the membrane-anchoring sequence
(Gonzalez et al., 1984) (Figure 4A).
However, hybridization of mouse genomic DNA
obtained from wild-type and PBGD-/- mice with the 294-
bp probe revealed that, most likely, only one cyp1a1 gene
product exists in the mouse, independent of the geno-
type (Figure 4B). Therefore, the solubility of CYP1A1 in
brain may not originate from an allelic or splice variant of
the cyp1a1 gene.
Discussion
CYP1A1 is expressed predominantly in extrahepatic tis-
sue and abundantly in brain (McFayden et al., 1998; Iba
et al., 2003). Our previous in vitro studies have suggested
that heme deficiency leads to increased accumulation of
CYP1A1 in the cytosol of COS-1 cells and untreated
male mice (Meyer et al., 2002). This is supported by
the present in vivo data in female PBGD-/- mice. The
PBGD-/- mouse provides a unique model of chronic
impairment of heme synthesis (Lindberg et al., 1996,
1999). After b-NF-treatment, the chronic partial heme
deficiency in these mice led to impaired CYP1A1 expres-
sion and enzyme activity in mouse liver and brain. More
surprisingly, CYP1A1 protein and activity were detected
in increased amounts in the cytosol of mouse brain after
b-NF treatment of PBGD-/- mice compared to wild-type
mice. The use of female mice in the present in vivo study
has the advantage that, in contrast to males (Meyer
et al., 2002), in untreated mice, CYP1A1 mRNA, protein
and EROD activity were not detectable in both liver and
brain. CYP1A1 protein is known to be highly inducible in
several brain regions, corresponding to elevated levels of
microsomal EROD activity (Morse et al., 1998). Therefore,
the genotype-dependent effects of the CYP1A1 inducer
b-NF on heme content, CYP1A1 expression and enzyme
activity under conditions of chronic heme deficiency, as
investigated in the present study, substantially extend
data from our previous in vitro study mimicking the
untreated situation (Meyer et al., 2002).
We have speculated that the availability of heme effi-
ciently regulates the incorporation of apocytochrome
CYP1A1 into the ER membrane, at least in extrahepatic
tissue. Interestingly, this effect of heme deficiency, lead-
ing to cytosolic accumulation of CYP1A1, is not
observed in the liver (Omiecinski and Juchau, 1980; Mey-
er et al., 2002). This can be explained by the efficient
adaptation of ALAS-1 to increased heme demands, such
as drug treatment, in liver and intestine, which is medi-
ated by nuclear receptor signaling by CAR and PXR (Fra-
ser et al., 2003). In extrahepatic tissue, ALAS-1 obviously
adapts differently to heme demands or drug treatment,
as stimulation of ALAS-1 by drugs is less marked than
in the liver (Reed et al., 1989). Although the brain pro-
duces heme required for synthesis and turnover of its
own hemoproteins (De Matteis et al., 1981), most of the
constitutively synthesized heme is used for cell homeo-
stasis and the generation of carbon monoxide and nitric
oxide, and is not drug inducible (Ingi et al., 1996; Jover
et al., 2000; da Silva et al., 2001). Heme oxidation in brain
is effectively controlled and balanced by the activity of
the heme oxygenase isoforms HO-1 and HO-2 (Maines,
2000).
Moreover, administration of exogenous heme to por-
phyria patients and to healthy volunteers increased
P450-mediated drug metabolism (Bonkovsky et al.,
1991). Our present study suggests that this increase is
due to heme effects in extrahepatic tissues, reconstitut-
ing undersaturated apocytochromes and/or leading to
greater incorporation of cytoplasmic apocytochromes
into the ER membrane, elevating their enzyme activity.
This concept is corroborated by significantly enhanced
levels of cytosolic EROD activity in b-NF-treated mice
after the exogenous addition of hematin. Extrahepatic
CYP apoproteins are reported to have low affinity for their
heme prosthetic group, but a comparatively high turn-
over number when in the holoenzyme state (Omiecinski
et al., 1980). The effect of hematin in lowering microso-
mal EROD activity may be explained by the fact that,
after induction, the membrane-bound fraction of CYP1A1
is in the holoenzyme state and excessive heme may be
inhibitory (Namkung et al., 1983). Conversely, this con-
cept of high turnover numbers of extrahepatic CYPs in
the holoenzyme state can most likely explain our finding
that, if no exogenous heme is added, there is largely no
difference in microsomal EROD activity after b-NF induc-
tion between wild-type and PBGD-/- mice, whereas
CYP1A1 protein is clearly reduced in PBGD-/- mice.
The mechanistic aspects of heme incorporation into
CYP apoproteins and the role of this process in
membrane incorporation is still poorly understood. Our
observation that heme deficiency leads to cytosolic
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Figure 2 Expression of CYP1A1 protein in subfractions of liver and brain of wild-type and PBGD-/- mice.
Scanning densitometry evaluation of immunoblots with monoclonal antibodies mab 1-7-1 raised against CYP1A1 (Park et al., 1982).
(A) CYP1A1 immunoblot of liver subfractions from female mice. Values represent a pool of two untreated animals and a pool of two
b-NF-treated animals of each genotype (mean"SEM; ns3) The mapped blot is a representative of these experiments. (B) CYP1A1
immunoblot of brain subfractions from female mice. Values represent a pool of four untreated animals and a pool of two b-NF-treated
animals of each genotype (mean"SEM; untreated, ns3; b-NF-treated, ns4). The mapped blot is a representative of these experi-
ments. Protein from 9000 g supernatant (9s), microsomes (mc) and cytosol (cyt) were separated by SDS-PAGE. Immunosignals were
visualized using enhanced chemiluminescence (ECL). Statistical significance is demonstrated by asterisks (***pF0.001; *pF0.05; n.s.,
not significant).
accumulation of CYP1A1 may be important for further
clarification of this process. Several previous studies pro-
vided evidence for the concept that heme incorporation
and exchange as well as membrane insertion of CYP iso-
forms is a dynamic process between the cytoplasm and
ER membranes. The biosynthesis of apocytochrome was
shown to precede that of heme, so that incorporation of
heme into the nascent apoprotein must take place prior
to or in close relation to membrane insertion (Meier et al.,
1984; De Matteis and Marks, 1996). Furthermore, CYP
heme can dissociate reversibly from its apoprotein to
allow heme exchange (Bissell and Hammaker, 1976a). It
was suggested from studies in testis that a less stable
form of CYP may be present in extrahepatic tissues that
shows impaired association with heme (Maines and
Jollie, 1984). These data corroborate our findings that a
small but significantly regulated fraction of enzymatically
active CYP1A1 holoenzyme is present in the cytosol of
wild-type and PBGD-/- mice (Figure 3A).
We presume that the availability of heme differentially
regulates the amount of specific CYP isoforms. We have
demonstrated that partial chronic heme deficiency led to
Mouse brain CYP1A1 in chronic heme deficiency 1161
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Figure 3 Formation of resorufin by 7-deethylation of 7-ethoxyresorufin in subfractions of mouse total brain from untreated and
b-NF-treated wild-type and PBGD-/- mice.
Incubations were performed with 6 mM 7-ethoxyresorufin (A) and in the presence of 8 mM hematin (B). Values represent a pool of
four untreated animals, and a pool of two b-NF-treated animals of each genotype (mean"SEM; ns3). Statistical significance is
demonstrated by asterisks (***pF0.001; **pF0.005; *pF0.05; n.s., not significant).
Figure 4 Detection of gene products of CYP1A1 and PBGD
with gene-specific probes by Southern blot analysis.
(A) Schematic representation of cyp1a1 gene and mRNA struc-
ture. Localization of the cyp1a1 gene-specific probe, the heme-
binding domain and the membrane-anchoring domain are
indicated. (B) Phosphoimage of the hybridization of genomic
DNA from wild-type and PBGD-/- mice with wa-32Px-ATP-labeled
CYP1a1 and PBGD gene-specific probes. The DNA was digest-
ed with EcoRI.
less potent induction of cyp1a1 mRNA in liver after treat-
ment of PBGD-/- mice with b-NF. This is consistent
with significant inhibition of CYP2A5 in liver of these
PBGD-/- mice after phenobarbital treatment (Jover et al.,
2000). The mechanism by which impaired heme synthe-
sis decreases CYP expression is not completely under-
stood and is still the subject of some controversy. Several
reports demonstrate that heme stabilizes the mRNA of
target genes and is therefore required for effective gene
transcription, e.g., for CYP1A1, CYP2B1/2 and HO-1
(Kloepper-Sams and Stegeman, 1994; Sultana et al.,
1997; Alam et al., 2003). Consistent with these studies,
we speculate that heme deficiency may lead to impaired
CYP1A1 mRNA stability, which results in reduced
gene transcription. However, other studies showed that
some CYP isoforms, including cyp2b10 and CYP2B1/2,
revealed less or no modulation of CYP mRNA in liver by
partial heme deficiency (Hamilton et al., 1988; Jover et
al., 2000). Furthermore, other hemoproteins, namely neu-
ronal nitric oxide synthase and soluble guanylate cyclase,
are reported to function normally in mice with limited
heme (Jover et al., 2000). Our findings are in agreement
with previous clinical studies in porphyria patients and
healthy volunteers showing that the effect of heme in
increasing drug metabolism is related to specific CYP
isoforms (Mustajoki et al., 1994). Currently, we are inves-
tigating the isoform specificity of this effect using GFP-
fused CYP1A, CYP2C, and CYP3A isoforms. This may
provide information about subcellular localization and the
regulation of these CYPs after drug treatment or phar-
macologically induced heme deficiency.
In conclusion, the results of the present study suggest
that partial chronic heme deficiency affects cyp1a1
expression, as well as CYP1A1 holoenzyme function. In
partial heme deficiency, CYP1A1 in brain is incompletely
saturated with heme. Incorporation of the isoform into ER
membranes is impaired and it remains in the cytosol.
Consequently, the enzyme activity of CYP1A1 is altered.
This concept may apply to other extrahepatic P450 cyto-
chromes and other hemoproteins. Diseases causing
heme deficiency, such as AIP, could apparently lead to
impaired hemoprotein function in brain. It has been
strongly suggested that symptoms such as autonomic or
peripheral neuropathies originate from such impaired
brain hemoprotein function rather than from the putative
neurotoxic heme precursor d-aminolevulinic acid (ALA),
as the neuropathy in PBGD-/- mice developed in the pres-
ence of almost normal ALA levels (Lindberg et al., 1999;
Schuurmans et al., 2001; Sassa, 2002). Therefore, the
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present study on CYP1A1 regulation in heme-deficient
mice may contribute to the understanding of CYP func-
tion and regulation in brain and the proceeding mecha-
nisms in chronic heme deficiency.
Materials and methods
Animals
Three female C57Bl/6J mice (age 1 year) of each genotype (wild
type or PBGD-/-) were injected twice intraperitoneally with 80 mg
b-NF/kg in corn oil. Four female wild-type mice were used as
controls. The animals were maintained in a 12-h light/dark cycle
in a controlled-environment animal facility and had free access
to standard rodent chow and tap water. Mice were anesthetized
with sodium pentobarbital, the left ventricle of the heart was
punctured and the animal was perfused with cold isotonic saline
to remove blood from the organs. Livers and brains were
excised, frozen in liquid nitrogen and stored at -808C until use.
Chemicals
7-Ethoxyresorufin, resorufin, and b-NF were purchased from
Aldrich (Buchs, Switzerland). Bovine serum albumin and NADPH
were obtained from Sigma (Buchs, Switzerland). Glucose-6-
phosphate, glucose-6-phosphate dehydrogenase, PCR free
nucleotide premix and the DNA ladder were purchased from
Roche Diagnostics (Mannheim, Germany). Protoporphyrin IX flu-
orescence standard and hemin were purchased from Porphyrin
Products (Logan, UT, USA). Trizol-RNA preparation kit and
M-MLV reverse transcriptase were obtained from Life Technol-
ogies (Basel, Switzerland). Gel purification and DNA preparation
kits were purchased from Qiagen (Basel, Switzerland). For clon-
ing, the pGEM-T easy vector (Promega-Catalys AG, Wallisellen,
Switzerland) was used. Taq-DNA polymerase was obtained from
Perkin-Elmer (Rotkreuz, Switzerland). PCR primers were synthe-
sized by Intron (Kaltbrunn, Switzerland). All other reagents were
from commercial sources at the highest purity available.
RNA purification, cDNA synthesis and probe
generation
Total RNA of frozen tissue was isolated using the Trizol-RNA
purification protocol (Life Technologies). RNA was reverse-tran-
scribed in 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 10 mM dithio-
threitol (DTT), 3 mM MgCl2, 200 mM of each deoxynucleotide
triphosphate, 200 U/mg RNA M-MLV reverse transcriptase, 28 U
of ribonuclease inhibitor (RNAsin, Promega, Madison, WI, USA)
and 2 mM oligowdT14(A/C/G)x primer. The mixture was incubated
at 408C for 1 h.
Specific primers for the gene-specific cyp1a1 probe were
designed as follows: the cyp1a1 forward primer (sense strand)
corresponded to nucleotides 1375–1393 (59-GGG TGA CCC
AAA CGA GTT-39), and the cyp1a1 reverse primer to nucleotides
1669–1687 (59-TGA AGA TGC TGA GGA CCA-39) (GenBank
accession number K02588). As a loading control, a gene-spe-
cific probe for detection of the standard sn-glyceraldehyde-
phosphate dehydrogenase (GAPDH) was used (Lindberg et al.,
1996).
Analysis of mRNA using Northern blotting
For analysis of mRNA by the Northern blot technique we gen-
erally followed the protocol described by Sambrook et al. (1989).
A 5-mg sample of liver total RNA was subjected to denaturing
electrophoresis on 1% agarose formaldehyde gels using 3-(N-
morpholino)propanesulfonic acid (MOPS) as buffering substance
as described by Sambrook et al. (1989). The gel was run for 4 h
at 80 V (constant voltage). RNA was then transferred to a nylon
membrane (GeneScreen, NEN Research Products, Boston, MA,
USA) by blotting overnight in 10= SSC buffer (150 mM NaCl,
15 mM sodium citrate). The RNA was attached to the membrane
by UV cross-linking (Stratagene, Basel, Switzerland). Hybridi-
zation was carried out in buffer containing 50% deionised for-
mamide, 5= SSC, 5= Denhardt’s solution, 1% SDS and 10%
(w/v) dextran sulfate. Before being added to the hybridization
solution, the PCR-labeled probe was boiled for 5 min in 300 ml
of 10 mg/ml salmon sperm DNA and quickly chilled on ice.
Hybridization was carried out for 20 h at 428C. Washes were
performed in 2= SSC/0.1% SDS at RT for 30 min and in 2=
SSC/1% SDS at 658C for 10–20 min. Membranes were exposed
to X-ray film using intensifying screens.
Analysis of genomic DNA using Southern blotting
Genomic DNA from wild-type and PBGD-/- mice was used for
Southern blotting. The DNA was digested with EcoRI and trans-
ferred to a GeneScreen nylon membrane as described by Lind-
berg et al. (1996). Hybridization was carried out in buffer
containing 1 M NaCl, 1% SDS and 10% (w/v) dextran sulfate.
Before being added to the hybridization solution, the w32Px-PCR-
labeled probe was boiled for 5 min in 400 ml of 10 mg/ml salmon
sperm DNA and quickly chilled on ice. Hybridization was car-
ried out for 15 h at 658C. Washes were performed twice in 2=
SSC/0.1% SDS at RT for 5 min and in 2=SSC/1% SDS at 658C
for 10–20 min. Membranes were exposed to X-ray film using
intensifying screens.
Homogenization and subfractionation of mouse
tissue
Homogenization and subfractionation of mouse tissue was per-
formed as described previously (Meyer et al., 2002). Homoge-
nate was centrifuged at 9000 g (Omiecinski et al., 1980). The
9000 g supernatant was then ultracentrifuged at 170 000 g (rmax)
for 30 min at 48C using a Beckman TLA120.2 rotor in a Beckman
bench-top ultracentrifuge. The 170 000 g pellet was designated
as ‘microsomes’, and the 170 000 g supernatant as ‘cytosol’.
The protein content of the subfractions was measured according
to Lowry et al. (1951). NADPH-cytochrome P450 oxidoreductase
was used as a marker to check membranous contamination of
the cytosol (Na¨slund et al., 1988). All methods used were proved
to generate high-integrity subcellular organelles and cytosol with
negligible membranous contamination (Meyer et al., 2002).
Ethoxyresorufin-O-deethylase (EROD) assay
EROD was measured according to the method of Burke et al.
(1985), using an end-point fluorimetric determination. Samples
equivalent to a protein amount of 40 mg for liver or 200 mg for
brain were preincubated in 100 mM sodium phosphate buffer,
pH 7.4, containing 20% glycerol, 0.2 mM EDTA, 0.5 mM DTT,
5 mM MgC12, 1 mg/ml bovine serum albumin, 6 mM substrate,
and 3.4 mg of purified rat cytochrome c reductase for 2 min at
378C. NADPH (0.5 mM) was added and the reaction was allowed
to proceed for 15 min or 2 h at 378C in darkness and under
100% oxygen (Omiecinski et al., 1980). Freshly prepared hema-
tin (Correia and Meyer, 1975) at a concentration of 8 mM was
added to the reaction mixture 5 min after the start. Incubation
was stopped by the addition of methanol and the mixture was
centrifuged at 14 000 g for 10 min. Fluorescence of the product
and identically handled resorufin standards were measured
using a Perkin-Elmer LS50B luminescence photometer (Perkin
Elmer). An identical set of samples boiled for 15 min at 958C
was used as blanks.
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Immunoblot using monoclonal antibody mab-1-7-1
against CYP1A1
Protein from subfractions of liver (50 and 5 mg/lane for untreated
and b-NF-treated mice, respectively) and brain (500 mg/lane)
was precipitated with methanol and resolved on 9% SDS poly-
acrylamide gels. Proteins were transferred to polyvinylidene
difluoride (PVDF) membranes (Immobilon P, Millipore AG, Vol-
ketswil, Switzerland) in buffer (125 mM Tris, 960 mM glycine).
Incubations were performed with anti-CYP1A1 monoclonal anti-
body mab-1-7-1 (diluted 1:500) (Park et al., 1982), followed by
exposure to horseradish peroxidase-conjugated IgG (goat anti-
mouse) at a dilution of 1:3000. The immunopositive bands were
visualized with enhanced chemiluminescence (ECL; Amersham-
Pharmacia GmbH, Du¨bendorf, Switzerland). The intensity of the
immunostained bands was evaluated by scanning densitometry
using Tina 2.10 software (Raytest GmbH, Straubenhardt, Ger-
many), and the results were analyzed statistically.
Heme determination
Heme content was determined by measurement of protopor-
phyrin IX fluorescence as previously described (Carvalho et al.,
1997; Meyer et al., 2002). Brain or liver tissue was treated with
2 M oxalic acid (100 ml) at 958C for 30 min. Samples were sub-
sequently resuspended in 900 ml of PBS and centrifuged at
15 000 g for 15 min. Fluorescence emission in the supernatant
was determined spectrofluorimetrically (Perkin Elmer LS50B).
Excitation and emission wavelengths were set to 405 and
600 nm, respectively. The background was evaluated by meas-
uring fluorescence in non-boiled samples. A standard curve of
protoporphyrin IX was run in parallel.
Statistical analysis
Data were analyzed statistically using an unpaired two-group
t-test (two-tailed t-test) to demonstrate the influence of both
b-NF treatment and genotype. Data processing was performed
using Microsoft Excel 2003 and SPSS 11.0.1 software. Results
were considered significant with pF0.05 for alterations due to
b-NF treatment or genotype. In cases where b-NF or different
genotype did not cause an effect (p)0.05) the results were con-
sidered not significant (n.s.).
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